Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.



trial #
trial description
  • Alliance A061202
  • The purpose of this study is to compare the effects, good and/or bad, of the study drugs pomalidomide, ixazomib, and dexamethasone, or the study drugs pomalidomide and dexamethasone, on you and your multiple myeloma to find out which is better. In this study, you will get either the study drugs pomalidomide, ixazomib, and dexamethasone or the study drugs pomalidomide and dexamethasone.

  • Alliance A061402
  • The purpose of this study is to compare any good and bad effects of using a combination of lenalidomide, ixazomib, dexamethasone, and zoledronic acid along with the radiation therapy to using radiation therapy and zoledronic acid alone for your plasmacytoma of the bone.

  • CTSU E1A11
  • The treatment of multiple myeloma has significantly changed as a result of several drugs being introduced for its treatment such as bortezomib, carfilzomib and lenalidomide. All these drugs used with dexamethasone or in combinations that contain more than one of these drugs allow greater control of the disease process. However, we still do not fully understand the best way to combine these drugs and how long the treatment process needs to be continued in order to provide the maximum benefit to the patients. The treatment combinations that are being compared in this study are both effective, but they have different side effects, which can impact whether patients tolerate the treatment for a prolonged time.  

  • SWOG S1211
  • One of the standard treatments for Multiple Myeloma is the combination of bortezomib, lenalidomide and dexamethasone (RVD).  Elotuzumab is a  research cancer drug.  It is currently being tested in cancer patients.  There are laboratory results that suggest that RVD might work better if elotuzumab is added.